Is PerkinElmer, Inc. (PKI) a leader in the diagnostics and research industry?

PerkinElmer, Inc. (PKI) is at the top of the diagnostics and research industry according to InvestorsObserver. PKI received an overall rating of 68, meaning it scores above 68% of all actions. PerkinElmer, Inc. also scored 98 in the diagnostics and research industry, which puts it above 98% of the diagnostics and research stocks. Diagnostics & Research is ranked 111 out of 148 industries.

PKI has an overall score of 68. Find out what this means for you and get the rest of the rankings on PKI!

What do these notes mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks to determine which ones perform best. InvestorsObserver makes the whole process easier by using percentile rankings that make it easy for you to find the stocks that have the strongest analyst valuations. These scores are not only easy to understand, but it’s also easy to compare stocks to each other. You can find the best stocks in an industry or find the sector with the highest average score. The overall score is a combination of technical and fundamental factors that provides a good starting point when analyzing a security. Traders and investors with different goals may have different goals and will want to consider other factors than just the overall number before making investment decisions.

What’s going on with PerkinElmer, Inc. stock today?

PerkinElmer, Inc. (PKI) stock is trading at $180.65 at 2:15 p.m. on Friday, February 11, down -$3.65, or -1.98% from the previous closing price of $184.30. The stock has traded between $178.92 and $185.10 so far today. Today, the volume is below average. So far, 305,291 shares have been traded with an average volume of 1,116,693 shares. Click here for the full PerkinElmer, Inc. stock report.

Stay in the know

Subscribe to our daily morning update newsletter and never miss market news, moves and more.

Thank you for signing up! You are ready to receive the Morning Update newsletter

Comments are closed.